1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow E10030 aptamer: new trials by email Literature Review of E10030 aptamer trials Research Report on E10030 aptamer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab, E10030 - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 3 | 2017-01-23 | 2021-11-01 |
National Eye Institute (NEI) (1)
United States (1)